As of September 30, 2026, Vitrolife AB carries a market capitalization of 1.16B, placing it among publicly traded companies globally. Its enterprise value stands at 1.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.16B |
| Enterprise Value | 1.24B |
Vitrolife AB's next confirmed earnings release is scheduled for January 28, 2027.
| Earnings Date | 1/28/2027 |
As of September 30, 2026, Vitrolife AB has 127.21M shares outstanding.
| Shares Outstanding | 127.21M |
These figures are as of September 30, 2026. The price-to-sales ratio is 3.42, and the price-to-book ratio stands at 1.42.
| PS Ratio | 3.42 |
| PB Ratio | 1.42 |
| P/TBV Ratio | -45.85 |
| P/FCF Ratio | 17.76 |
| P/OCF Ratio | 16.90 |
These figures are as of September 30, 2026. The EV/Sales ratio of 3.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.24B versus a market cap of 1.16B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 3.61 |
As of September 30, 2026, Vitrolife AB maintains a current ratio of 3.68, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.68 |
| Quick Ratio | 1.40 |
| Debt / Equity | 21.25 |
| Debt / EBITDA | -0.36 |
These figures cover the twelve months ended September 30, 2026. The company generates approximately 298,783.97 in revenue per employee across its workforce of 1,151.00, a quick read on workforce productivity versus industry peers.
| Revenue Per Employee | 298,783.97 |
| Employee Count | 1,151.00 |
Over the twelve months ended September 30, 2026, Vitrolife AB recorded 14.40M in income tax expense. The company reported a pretax loss of -481.60M and -495.70M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 14.40M |
As of the close on October 14, 2026, Vitrolife AB's stock has declined approximately 31.70% over the past 52 weeks.
| 52-Week Price Change | -31.70% |
| 50-Day Moving Average | 18.12 |
Over the twelve months ended September 30, 2026, Vitrolife AB generated 343.90M in revenue and converted that into -495.70M in net income, yielding earnings per share of -3.83. EBITDA reached -474.20M, while operating income came in at -474.20M.
| Revenue | 343.90M |
| Gross Profit | 204.00M |
| Operating Income | -474.20M |
| Pretax Income | -481.60M |
| Net Income | -495.70M |
| EBITDA | -474.20M |
| EBIT | -474.20M |
| Earnings Per Share (EPS) | -3.83 |
As of September 30, 2026, Vitrolife AB holds 86.00M in cash and equivalents against 172.50M in total debt, resulting in a net debt position of 74.30M. Total book value stands at 811.80M, with working capital of 164.40M providing operational flexibility.
| Cash & Cash Equivalents | 86.00M |
| Total Debt | 172.50M |
| Net Debt | 74.30M |
| Equity (Book Value) | 811.80M |
| Book Value Per Share | 6.38 |
| Working Capital | 164.40M |
Vitrolife AB produced 69.60M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -3.40M in capital expenditures, free cash flow totaled 66.20M - equivalent to 0.51 per share.
| Operating Cash Flow | 69.60M |
| Capital Expenditures | -3.40M |
| Free Cash Flow | 66.20M |
| FCF Per Share | 0.51 |
Over the twelve months ended September 30, 2026, Vitrolife AB posted a gross margin of 59.32, reflecting its pricing power and cost economics. The operating margin of -137.89 and net profit margin of -144.14 provide insight into operational efficiency.
| Gross Margin | 59.32 |
| Operating Margin | -137.89 |
| Pretax Margin | -140.04 |
| Profit Margin | -144.14 |
| EBITDA Margin | -137.89 |
Over the twelve months ended September 30, 2026, Vitrolife AB paid dividends of 0.12 per share. The dividend payout ratio of -3.00 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.63, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vitrolife AB shareholders.
| Dividend Per Share | 0.12 |
| Payout Ratio | -3.00 |
| Shareholder Yield | 6.50 |
| FCF Yield | 5.63 |
Vitrolife AB's most recent stock split took place on June 1, 2018 with a 4:5 split ratio.
| Last Split Date | 6/1/2018 |
| Split Ratio | 4:5 |
As of September 30, 2026, Vitrolife AB has an Altman Z-Score of -4.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.37 |
Already premium?